BioMarin Pharmaceutical stock
Price history
+5.55% over the period1 year: from $54.22 (November 13, 2025) to $57.23 (November 13, 2026), +5.55%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $57.23 |
| October 30, 2026 | $58.51 |
| September 30, 2026 | $60.00 |
| August 31, 2026 | $65.23 |
| July 31, 2026 | $60.02 |
| June 30, 2026 | $57.22 |
| May 29, 2026 | $57.29 |
| April 30, 2026 | $53.91 |
| March 31, 2026 | $56.49 |
| February 27, 2026 | $61.73 |
| January 30, 2026 | $56.54 |
| December 31, 2025 | $59.43 |
| November 28, 2025 | $55.93 |
| November 13, 2025 | $54.22 |
At a glance
The company
Biotechnology company developing and commercializing therapies for rare genetic and metabolic disorders globally
Latest results
Quarter to September 30, 2026 · EPS $0.23 (estimate $1.35)
TickerLandia's take on BioMarin Pharmaceutical
- Priced as usual relative to earnings: P/E on the latest fiscal year 32 vs a median of 33 over its last 5 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 147 vs 55 (+168%) in a group of 7.
- Strong point: Earnings stability (71/100 in its group). Weak point: Profitability (33/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−19.37% from the 52-week high
Analysts · 28 analysts
Average target$90.78+58.62% vs. price
Buy 21 · Hold 7 · Sell 0 · Buy
TickerLandia Fingerprint: BioMarin Pharmaceutical
Compared with similar companies: high earnings stability, low price, and low risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow30
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 146.8 94 Forward P/E 9.05 3 Price/book 1.77 9 Price/sales 3.03 11 EV/EBITDA 17.0 33 Profitabilitylow33
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 16.3% 43 Gross margin 53.2% 29 Net margin −0.5% 24 ROE −0.3% 28 ROA 3.9% 41 Earnings stabilityhigh71
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 8.0% 80 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 62 Growthaverage43
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +15.40% 43 Revenue growth (year over year) +32.00% 65 Earnings growth (year over year) −81.30% 23 Financial strengthaverage49
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.93 78 Interest coverage 59.7 73 Debt/equitycounts in reverse: lower means more financial strength 0.67 14 Current ratio 2.44 32 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumweak36
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −13.87% 17 Relative strength (6 months) +5.21% 54 1-year return +5.55% 39 Distance from 200-day average −2.11% 35 Risklow32
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 22.6% 34 Beta (1 year) 0.36 34 Volatility (60 days) 26.9% 30
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
BioMarin Pharmaceutical is priced as in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), BioMarin Pharmaceutical's P/E today is 31.8, in line with the median of its last 5 fiscal years (33.0; between 19.5 and 138.0 from 2020 to 2025). BioMarin Pharmaceutical's P/E (trailing 12 months): 146.8, +168% against the median of a group of 7 similar companies (54.8).
Compared with 7 similar companies
| Metric | BioMarin Pharmaceutical | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 146.8 | High | |
| Forward P/E | 9.05 | Low | |
| Operating margin | 16.3% | Middle | |
| ROE | -0.3% | Middle | |
| Debt/equity | 0.67 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: BioMarin Pharmaceutical. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$989.71M
Latest quarter · Q2 2026
Net income
$44.76M
Latest quarter · Q2 2026
Quarterly net margin
4.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $11.09B
- P/E
- 146.8
- EPS
- -$0.10
- Volume
- 1.47M
- Daily trading
- €126.22M
- Dividend yield
- 0.00%
How BioMarin Pharmaceutical is changing
All resultsRevenue grew 11.6% a year on average over the last 5 years
Operating margin rose from 7.7% to 12.7%
Profits turn into cash: free cash flow equal to 135% of net income
Returns
BioMarin Pharmaceutical returns
$1,000 invested in BioMarin Pharmaceutical 5 years ago, on November 15, 2021, would be worth $697 today: −30.27% in total, −6.96% per year. This is the price return only: dividends are excluded.
| Period | BioMarin Pharmaceutical | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +5.24% | −3.12% | $1,052 |
| 6 months | +6.87% | +1.58% | $1,069 |
| Year to date | −3.70% | +10.46% | $963 |
| 1 year | +5.55% | +12.23% | $1,056 |
| 3 years | −31.37% | +71.41% | $686 |
| 5 years | −30.27% | +61.48% | $697 |
| 10 years | −38.40% | +249.40% | $616 |
Over the last 6 months it has done better than 34% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
BioMarin Pharmaceutical: technical analysis
BioMarin Pharmaceutical shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 61.6% below its all-time closing high ($149.13, July 20, 2015).
- Trend
- No clear trend
- RSI (14 sessions)
- 50
- Between 30 and 70
- vs 200-session average
- −2.11%
Support and resistance
Price areas where BioMarin Pharmaceutical has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$60.65+5.98%2 touches, last on July 17, 2026
- Resistance$59.39+3.77%3 touches, last on November 2, 2026
- Resistance$57.95+1.26%9 touches, last on October 15, 2026
- Last price$57.23
- Support$53.90−5.82%4 touches, last on October 8, 2026
- Support$52.15−8.88%3 touches, last on November 3, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.36
- Volatility (60 sessions, annualised)
- 26.9%
- Largest fall in the last year
- −22.58%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
BioMarin Pharmaceutical: seasonality
Average monthly price change over 28 years
Over the last 28 years, the strongest month for BioMarin Pharmaceutical has been November: +6.09% on average, positive in 22 years out of 27. The weakest has been October: −2.64% on average, positive in 11 years out of 28.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.60% | +3.30% | 17 of 27 |
| February | +1.61% | −2.04% | 13 of 27 |
| March | +0.19% | −0.66% | 12 of 27 |
| April | −2.05% | 0.00% | 13 of 27 |
| May | +0.79% | +2.71% | 14 of 27 |
| June | +1.65% | +3.63% | 16 of 27 |
| July | +3.99% | +3.84% | 18 of 27 |
| August | +0.50% | +1.00% | 16 of 28 |
| September | −1.49% | −2.75% | 12 of 28 |
| October | −2.64% | −3.13% | 11 of 28 |
| November | +6.09% | +5.74% | 22 of 27 |
| December | +3.51% | +2.49% | 17 of 27 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
BioMarin Pharmaceutical and its competitors
The company's activity centres on rare-disease therapies, with a portfolio built around enzyme replacement treatments and peptide-based medicines. Its marketed products include VIMIZIM for mucopolysaccharidosis type IV A, VOXZOGO for achondroplasia, NAGLAZYME and ALDURAZYME for other MPS disorders, PALYNZIQ for lowering blood phenylalanine, BRINEURA for Batten disease type 2, and KUVAN for phenylketonuria. Two candidates in development, BMN 333, a longer-acting CNP, and BMN 351, an oligonucleotide for Duchenne muscular dystrophy, extend the pipeline.
- Headquarters
- San Rafael, United States
- Employees
- 3,221
- Founded
- 1996
- Chief executive
- Alexander Hardy
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| BioMarin PharmaceuticalBMRN | $11.09B | 16.3% | 146.8 | +6.87% |
| Summit TherapeuticsSMMT | $11.32B | 0.0% | — | −24.69% |
| Halozyme TherapeuticsHALO | $11.43B | 56.7% | 25.1 | +43.18% |
| Bio-TechneTECH | $11.44B | 21.7% | 66.8 | +62.17% |
| Madrigal PharmaceuticalsMDGL | $9.93B | -10.7% | — | −17.63% |
| BridgeBio PharmaBBIO | $15.25B | -37.3% | — | +14.12% |
Same industry or related industries, similar size. Compare BioMarin Pharmaceutical with its competitors · Full profile
